MeritValue

BIOTRICITY INC.

BTCYdata completeness 75%14 fiscal years on file

Data notes: no data for concept 'totalDebt'; no data for concept 'investmentsAtFairValue'; no data for concept 'netInvestmentIncome'; no data for concept 'gainsOnRealEstateSales'; no data for concept 'incomeTaxExpense'

i. The business — what you’d actually own
FigureFY 2022FY 2023FY 2024FY 2025FY 2026
Revenue$7.65M1$9.64M2$12.1M3$13.8M4$16M4
Net income−$29.1M5−$18.7M6−$14.1M7−$8.42M8−$2.4M8
Operating cash flow−$15.2M9−$13.5M10−$6.69M11−$2.38M12−$718,95512
Capital expenditure$29,76713————
Free cash flow (derived)−$15.2M9————
Total debt—————
Cash & equivalents$12.1M14$570,46015$786,06016$365,14517$149,78917
Diluted shares45.4M8.7M9.0M21.5M27.3M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$12.7
your share of equity
Profit it earned you last year
−$0.88
Free cash flow it threw off
—
Debt you’d be carrying
—

10 shares is a claim on −$12.7 of net worth that earned you −$0.88 last year.

iii. Is this a good business?
Moat signal · return on equity
— avg · 5y

Not enough data in the filings for a return-on-capital reading.

seeing a moat in the numbers →
Management signal · capital allocation
−40% shares · 5y

Share count is down 40% over 5 years — management has been buying back stock, quietly handing owners a bigger slice.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.5.0
DCF · Growth Exit 10Y
not applicable
only 1 years of FCF (need ≥3) — model not applicable
DCF · Growth Exit 5Y
not applicable
only 1 years of FCF (need ≥3) — model not applicable
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts
  1. 10-K · period ending 2022-03-31 · accession 0001493152-23-022974 (RevenueFromContractWithCustomerExcludingAssessedTax)
  2. 10-K · period ending 2023-03-31 · accession 0001493152-24-025344 (RevenueFromContractWithCustomerExcludingAssessedTax)
  3. 10-K/A · period ending 2024-03-31 · accession 0001641172-25-020105 (RevenueFromContractWithCustomerExcludingAssessedTax)
  4. 10-K · period ending 2025-03-31 · accession 0001493152-26-033207 (RevenueFromContractWithCustomerExcludingAssessedTax)
  5. 10-K · period ending 2022-03-31 · accession 0001493152-23-022974 (NetIncomeLoss)
  6. 10-K · period ending 2023-03-31 · accession 0001493152-24-025344 (NetIncomeLoss)
  7. 10-K/A · period ending 2024-03-31 · accession 0001641172-25-020105 (NetIncomeLoss)
  8. 10-K · period ending 2025-03-31 · accession 0001493152-26-033207 (NetIncomeLoss)
  9. 10-K · period ending 2022-03-31 · accession 0001493152-23-022974 (NetCashProvidedByUsedInOperatingActivities)
  10. 10-K · period ending 2023-03-31 · accession 0001493152-24-025344 (NetCashProvidedByUsedInOperatingActivities)
  11. 10-K/A · period ending 2024-03-31 · accession 0001641172-25-020105 (NetCashProvidedByUsedInOperatingActivities)
  12. 10-K · period ending 2025-03-31 · accession 0001493152-26-033207 (NetCashProvidedByUsedInOperatingActivities)
  13. 10-K · period ending 2022-03-31 · accession 0001493152-23-022974 (PaymentsToAcquirePropertyPlantAndEquipment)
  14. 10-K · period ending 2022-03-31 · accession 0001493152-23-022974 (CashAndCashEquivalentsAtCarryingValue)
  15. 10-K · period ending 2023-03-31 · accession 0001493152-24-025344 (CashAndCashEquivalentsAtCarryingValue)
  16. 10-K/A · period ending 2024-03-31 · accession 0001641172-25-020105 (CashAndCashEquivalentsAtCarryingValue)
  17. 10-K · period ending 2025-03-31 · accession 0001493152-26-033207 (CashAndCashEquivalentsAtCarryingValue)